Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex in proliferative vitreoretinopathy: a randomized controlled trial
2011-004498-96Phase 3Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Oct 2011
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of ozurdex in Proliferative Vitreoretinopathy (PVR) (2 arms), sponsored by Moorfields Eye Hospital. Primary endpoint: Stable retinal reattachment without further surgery at 6 months. Started Oct 2011; status: completed.
02
Drugs
ozurdex
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on 2011-004498-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004498-96.